Drug firm MSN Laboratories, on Friday, said it has entered into a license agreement with the Defense Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG), used for the treatment of COVID-19. Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, MSN Labs said in a statement.
“The company has entered into a license agreement with DRDE and the Institute of Nuclear Medicine and Allied Sciences (INMAS) establishments of DRDO for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG) in India,” it added.
“MSN labs will be launching the 2-DG as a twice-a-day product in sachet form under the brand name MSN 2D in strength of 2.34 g,” the statement said.
Read all the Latest News, Breaking News and Coronavirus News here.
Comments
0 comment